RADNOR, Pa. — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, will release its third quarter 2023… Read More
Completed Phase 2 Clinical Trial demonstrating anti-itch activity of INM-755 (CBN) topical cream $4.1M revenues in fiscal year 2023, representing a 280% increase over the previous fiscal year and $2.3M… Read More
HIGHLIGHTS • Advancements in genetic and genomic technologies allow for more customized health care called ‘precision health’. • For precision health technologies to be effective, health care providers and educators… Read More
BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)– Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab… Read More
The updated vaccine (XBB.1.5 variant-adapted monovalent COVID-19 vaccine) is now authorized in Canada for individuals 6 months of age and older The updated vaccine is administered as a single dose… Read More
